Comparison between Pine Labs IPO and Sudeep Pharma IPO.
Pine Labs IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Sudeep Pharma IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Pine Labs IPO is up to ₹3,900.17 Cr whereas the issue size of the Sudeep Pharma IPO is up to ₹895.00 Cr. The final issue price of Pine Labs IPO is ₹221.00 per share and of Sudeep Pharma IPO is ₹593.00 per share.
| Pine Labs IPO | Sudeep Pharma IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹1 per share |
| Issue Price (Lower) | ₹210.00 per share | ₹563.00 per share |
| Issue Price (Upper) | ₹221.00 per share | ₹593.00 per share |
| Issue Price (Final) | ₹221.00 per share | ₹593.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹21.00 per share | |
| Market Lot Size | 67 shares | 25 shares |
| Fresh Issue Size | 9,41,29,524 shares | 16,02,023 shares |
| Fresh Issue Size (Amount) | up to ₹2,080.26 Cr | up to ₹95.00 Cr |
| OFS Issue Size | 8,23,48,779 shares | 1,34,90,726 shares |
| OFS Issue Size (Amount) | up to ₹1,819.91 Cr | up to ₹800.00 Cr |
| Issue Size Total | 17,64,78,303 shares | 1,50,92,749 shares |
| Issue Size Total (Amount) | up to ₹3,900.17 Cr | up to ₹895.00 Cr |
Pine Labs IPO opens on Nov 07, 2025, while Sudeep Pharma IPO opens on Nov 21, 2025. The closing date of Pine Labs IPO and Sudeep Pharma IPO is Nov 11, 2025, and Nov 25, 2025, respectively.
| Pine Labs IPO | Sudeep Pharma IPO | |
|---|---|---|
| Anchor Bid Date | Nov 06, 2025 | Nov 20, 2025 |
| Issue Open | Nov 07, 2025 | Nov 21, 2025 |
| Issue Close | Nov 11, 2025 | Nov 25, 2025 |
| Basis Of Allotment (Tentative) | Nov 12, 2025 | Nov 26, 2025 |
| Initiation of Refunds (Tentative) | Nov 13, 2025 | Nov 27, 2025 |
| Credit of Share (Tentative) | Nov 13, 2025 | Nov 27, 2025 |
| Listing date (Tentative) | Nov 14, 2025 | Nov 28, 2025 |
| Anchor Lockin End date 1 | Dec 11, 2025 | Dec 26, 2025 |
| Anchor Lockin End date 2 | Feb 09, 2026 | Feb 24, 2026 |
Pine Labs IPO P/E ratio is -160.13, as compared to Sudeep Pharma IPO P/E ratio of 47.61.
| Pine Labs IPO | Sudeep Pharma IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Pine Labs Ltd.'s revenue increased by 28% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Sudeep Pharma Ltd.'s revenue increased by 10% and profit after tax (PAT) rose by 4% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 0 | 89.37 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 0 | 76.15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | -160.13 | 47.61 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹25376.65 Cr. | ₹6697.85 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹-1.38 | ₹12.46 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | -4.15% | 27.88% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Pine Labs IPO Retail Individual Investors (RII) are offered 1,76,35,330 shares while in Sudeep Pharma IPO retail investors are offered 1,76,35,330 shares. Qualified Institutional Buyers (QIB) are offered 5,29,05,992 shares in Pine Labs IPO and 30,18,550 shares in Sudeep Pharma IPO.
| Pine Labs IPO | Sudeep Pharma IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,93,58,986 shares | 45,27,823 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 5,29,05,992 shares | 30,18,550 shares |
| NII | 2,64,52,995 shares | 22,63,913 shares |
| RII | 1,76,35,330 shares | 52,82,463 shares |
| Employee | 1,25,000 shares | 0 shares |
| Others | ||
| Total | 17,64,78,303 shares | 1,50,92,749 shares |
Pine Labs IPO subscribed 2.48x in total, whereas Sudeep Pharma IPO subscribed 93.71x.
| Pine Labs IPO | Sudeep Pharma IPO | |
|---|---|---|
| QIB (times) | 3.97x | 213.08x |
| NII (times) | 0.30x | 116.72x |
| Big NII (times) | 0.25x | 134.91x |
| Small NII (times) | 0.42x | 80.33x |
| RII (times) | 1.27x | 15.65x |
| Employee (times) | 7.78x | |
| Other (times) | ||
| Total (times) | 2.48x | 93.71x |
